drugset
drugset / Trial / NCT03673696

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

NCT03673696 ↗

Phase 1 Completed 105 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects

Timeline

Start
2018-09-04
Primary completion
2019-07-02
Completion
2019-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC74647PA Unknown 50 mg Oral
Subject HEC74647PA Unknown 100 mg Oral
Subject HEC74647PA Unknown 200 mg Oral
Subject HEC74647PA Unknown 400 mg Oral
Subject HEC74647PA Unknown 600 mg Oral
Subject HEC74647PA Unknown 800 mg Oral

Indications

chronic hepatitis C virus infection